{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-010055","form_type":"8-K","ticker":"DYAI","cik":"0001213809","company_name":"DYADIC INTERNATIONAL INC","filed_at":"2023-04-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.179893+00:00","generated_at":"2026-06-17T02:57:04.562757+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Dyadic expands C1 platform licensing deal with Rubic One Health for Africa vaccines and biologics","bullets":["Expanded license covers vaccines and therapeutic proteins beyond COVID-19 for human and animal health.","Rubic to pay licensing fee on commercial sales; Dyadic receives equity in Rubic in 2028.","Milestones allow conversion to exclusive license for bulk manufacturing in SADC region.","DYAI-100 (COVID-19 vaccine candidate) is in Phase 1 first-in-human trial, enabling the expansion.","Agreement aims to develop affordable biologics for underserved African countries."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-010055","json":"https://secwatch.observer/filing/0001437749-23-010055.json","markdown":"https://secwatch.observer/filing/0001437749-23-010055.md","text":"https://secwatch.observer/filing/0001437749-23-010055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213809/000143774923010055/0001437749-23-010055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213809/000143774923010055/dyai20230410_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T02:57:04.562757+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7f5080e5a49554a1c19e4bc27f142a42b51bb019","claim":"DYADIC INTERNATIONAL INC entered into Expanded Licensing Agreement with Rubic One Health (effective 2023-04-06).","evidence_excerpt":"On April 6, 2023, Dyadic International (USA), Inc., a subsidiary of Dyadic International, Inc., (hereinafter collectively referred to as “Dyadic” or the “Company”) signed an expanded licensing agreement (“the Agreement”) for its C1-cell protein expression platform with South Africa’s Rubic One Health (“Rubic”) to research, develop, manufacture, commercialize and distribute affordable vaccines and biologics for human and animal health in underserved African countries.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1213809/000143774923010055/0001437749-23-010055-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Rubic One Health"},{"label":"Effective","value":"2023-04-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}